Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$28.09
--
Market closed
$28.09
--
Day’s Range― - ―
52-Week Range$9.83 - $53.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)526.33K
Market Cap
$1.73B
Enterprise Value$1.24B
Total Cash (Recent Filing)$352.38M
Total Debt (Recent Filing)$61.22M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 18, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding55,345,260
10 Day Avg. Volume659,433
30 Day Avg. Volume526,332
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue61.86
Enterprise Value/Gross Profit67.21
Enterprise Value/Ebitda-10.35
Forecast
1Y Price Target
$70.00Price Target Upside149.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$22.22M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayThe $150M registered offering materially reduces near-term financing risk and funds clinical development of lead candidates through multiple value inflection points. A multi-year runway allows management to advance trials without urgent dilution and supports sustained R&D execution.
Low Leverage / Equity CushionVery low debt and a sizable equity base provide financial flexibility typical for earlier-stage biotechs, reducing solvency risk. This balance-sheet strength supports continued clinical spending, partnering optionality, and the ability to withstand trial timing variability without forcing distressed financings.
Genetics-driven Precision-Medicine ModelA human genetics–based discovery engine is a durable competitive advantage: genetics-backed targets raise the probability of clinical success and enable differentiated programs in kidney and metabolic diseases. Focused small-molecule programs target clear unmet needs and long-term commercial niches.
Bears Say
Ongoing Cash BurnPersistent large negative operating and free cash flows indicate the business remains dependent on external financing. Over the medium term this creates dilution risk, constrains strategic optionality, and requires sustained investor access to fund costly clinical programs until revenues or partnerships emerge.
Revenue & Profitability VolatilityWide swings in revenue and profits show that cash generation is not yet durable or predictable. Such volatility undermines the company’s ability to self-fund R&D, complicates planning for commercialization, and increases the likelihood of future financings if clinical milestones or revenue growth do not stabilize.
Consolidation Of Finance LeadershipConcentrating accounting and finance duties under the CFO can streamline reporting but raises execution and oversight risk during a resource-intensive clinical development phase. This consolidation could strain capacity for complex financial planning, controls, and investor engagement over the medium term.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $9.83 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.73B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 43 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.577 by $0.127.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 55,345,260 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.577. Following the earnings report the stock price went up 4.577%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.00 (149.20% Upside)
$70.00 (149.20% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 214.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
163.57%
12-Months-Change
Fundamentals
Return on Equity
-36.63%
Trailing 12-Months
Asset Growth
26.10%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$70.00
▲(149.20% Upside)
Technical Analysis
Ownership Overview
11.08% Insiders
5.52% Mutual Funds
67.03% Other Institutional Investors
8.42% Public Companies and
Individual Investors